Bank of Marin cut its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 63.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,109 shares of the company’s stock after selling 5,467 shares during the period. Bank of Marin’s holdings in Johnson & Johnson were worth $482,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the business. GW&K Investment Management LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $35,000. Dark Forest Capital Management LP lifted its stake in Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth $42,000. Kepos Capital LP acquired a new position in Johnson & Johnson during the fourth quarter worth $45,000. Finally, VitalStone Financial LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $52,000. 67.57% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares of the company’s stock, valued at $10,549,440. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,163 shares of company stock valued at $7,928,856. 0.20% of the stock is currently owned by insiders.
Analyst Ratings Changes
Check Out Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $173.85 on Friday. The business’s fifty day moving average price is $164.56 and its 200 day moving average price is $161.21. The firm has a market capitalization of $451.83 billion, a PE ratio of 35.19, a price-to-earnings-growth ratio of 2.90 and a beta of 0.54. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.59 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.74%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Investing in Coffee: 3 Great Strategies to Consider
- What is ChatGPT Stock? How to Invest in It
- 5 Best Stocks to Buy in a Bear Market
- Best Aerospace Stocks Investing
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
